macitentan

macitentan Struktur
441798-33-0
CAS-Nr.
441798-33-0
Englisch Name:
macitentan
Synonyma:
5-(4-BROMOPHENYL)-6-[2-(5-BROMOPYRIMIDIN-2-YL)OXYETHOXY]-N-(PROPYLSULFAMOYL)PYRIMIDIN-4-AMINE;CS-643;Maximitan;ACT-064992;ACT 064992;macitentan;Actelion-1;Macitentan CRS;Macitentan, >=99%;Marcy for Tanzania
CBNumber:
CB81518520
Summenformel:
C19H20Br2N6O4S
Molgewicht:
588.27
MOL-Datei:
441798-33-0.mol

macitentan Eigenschaften

Siedepunkt:
692.4±65.0 °C(Predicted)
Dichte
1.675
storage temp. 
Store at -20°C
Löslichkeit
≥24.4 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
Aggregatzustand
solid
pka
4.99±0.50(Predicted)
InChI
InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)
InChIKey
JGCMEBMXRHSZKX-UHFFFAOYSA-N
SMILES
S(NC1C(C2=CC=C(Br)C=C2)=C(OCCOC2=NC=C(Br)C=N2)N=CN=1)(NCCC)(=O)=O
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Achtung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H360 Kann die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. Fertility (Fruchtbarkeit) Kategorie 1 Achtung GHS hazard pictogramssrc="/GHS08.jpg" width="20" height="20" />
Sicherheit

macitentan Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Macitentan (also known as ACT-064992) received US FDA approval in October 2013 for the treatment of pulmonary arterial hypertension (PAH) (WHO group I) to delay disease progression. Treatment options include phosphodiesterase type 5 inhibitors, prostacyclins, and the endothelin receptor antagonists bosentan and ambrisentan. Macitentan was discovered through SAR studies starting with the bosentan structure with three main goals: (1) to increase potency for both endothelin receptor A and B (ETA and ETB) subtypes; (2) to improve tissue distribution to reach the target receptors; and (3) to avoid bile salt transport inhibition. Starting with the bosentan sulfonamido-pyrimidinyl central core, potency was increased 10-fold via incorporation of a bromopyrimidinyl ethylene glycol ether, as found in the clinical endothelin antagonist, T-0201. An aryl ether in bosentan was replaced with the bromophenyl group in macitentan, and a substituent on the 2-position of the central pyrimidine was replaced with hydrogen. Several sulfonamides and alkyl sulfamates were explored, with the propylsulfamate providing the best combination of in vitro potency, especially for ETB antagonism, and in vivo efficacy.

Verwenden

Macitentan is an endothelin receptor antagonist that is used in the therapy of pulmonary arterial hypertension (PAH). It also reduced hospitalization for PAH. Macitentan was approved for PAH by the United States Food and Drug Administration (FDA) in 2013. Macitentan has been associated with a low rate of serum enzyme elevations during therapy, but has yet to be implicated in cases of clinically apparent acute liver injury.

Definition

ChEBI: Macitentan is a member of the class of sulfamides in which the two amino groups of sulfonamide are substituted by 5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl and propyl groups. An orphan drug used for the treatment of pulmonary arterial hypertension. It has a role as an endothelin receptor antagonist, an antihypertensive agent and an orphan drug. It is an organobromine compound, a member of pyrimidines, an aromatic ether, a ring assembly and a member of sulfamides. It is functionally related to an ethylene glycol and an ACT-132577.

Mode of action

Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity. Upon administration, macitentan and its metabolites block the binding of endothelin isoform 1 (ET-1) to type-A and type-B ETR on both the tumor cells and the endothelial cells in the tumor vasculature. This prevents ET-1 mediated signaling transduction which may decrease tumor cell proliferation, progression, and angiogenesis in tumor tissue. ET-1, a potent vasoconstrictor that plays an important role in inflammation and tissue repair, is, together with its receptors, overexpressed varyingly in many tumor cell types.

macitentan Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


macitentan Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 341)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Seasons Biotechnology Co., Ltd.
+86-0576-89232655 +86-13566878689
info@seasonsbio.com China 47 58
Unipharm pharmaceutical industry Co., Ltd
536-8266195 +8613953676784
lee@unipharm-sd.com China 1206 58
Hefei TianRui Pharmaceutical Chemical Co., Ltd.
+86-0551-68665055 +86-+86-18616906106
sales@trywchem.com China 129 58
Hebei Mojin Biotechnology Co., Ltd
+8613288715578
sales@hbmojin.com China 12468 58
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806
sales@capotchem.com China 29797 60
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21689 55
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714
fandachem@gmail.com China 9341 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 - 03@
sales03@shyrchem.com CHINA 738 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32686 60
Shandonghaohong biotechnology Co.,ltd.
0635-6175299 13961496334
sale@inyelchem.com CHINA 44 55

  • N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)-oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfami
  • macitentan
  • N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide
  • ACT 064992
  • ACT-064992
  • ACT-064992 / ACT064992
  • Macitentan, >=99%
  • SulfaMide,N-[5-(4-broMophenyl)-6-[2-[(5-broMo-2-pyriMidinyl)oxy]ethoxy]-4-pyriMidinyl]-N'-propyl-
  • N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide Macitentan
  • macitentan,CID 16004692
  • CS-643
  • Macitentan (ACT 064992
  • Macitentan (Actelion-1,ACT-064992)
  • Actelion-1
  • macitentan ISO 9001:2015 REACH
  • Macitentan (ACT-064992 D4)
  • 5-(4-BROMOPHENYL)-6-[2-(5-BROMOPYRIMIDIN-2-YL)OXYETHOXY]-N-(PROPYLSULFAMOYL)PYRIMIDIN-4-AMINE
  • Marcy for Tanzania
  • {[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]sulfamoyl}(propyl)amine
  • Macitentan tablet 10mg
  • Maximitan
  • Macitentan CRS
  • N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide
  • 441798-33-0
  • C19H20Br2N6O4S
  • Inhibitors
  • API
  • 441798-33-0
Copyright 2019 © ChemicalBook. All rights reserved